Drug Trial Radar · NCT07124884
5-fluorouracil Plus Panitumumab (Anti-EGFR) and Sotorasib (KRAS G12C Inhibitor) in First-line Treatment of Patients Non-eligible for a Doublet/Triplet Chemotherapy With Advanced Unresectab
Last checked: Nov 20, 2026Latest source record: Aug 15, 2025 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Not yet recruiting
Enrollment
300
Planned (sponsor's estimate)
Start
Aug 31, 2025
Primary completion
Jun 30, 2030
Study completion Dec 30, 2030
Sponsor
- Lead sponsor
- Federation Francophone de Cancerologie DigestiveAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- Collaborators
- Northwest Oncology Cooperative Group(GONO); Arbeitsgemeinschaft fur Internistische Onkologie; Spanish Cooperative Group for the Treatment of Digestive Tumours (TTD)
- First posted
- Aug 15, 2025
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
5-fluorouracil (5-FU) is a standard of care in frail/elderly patients with an unresectable colorectal adenocarcinoma (CRC) in first-line setting. Panitumumab plus Sotorasib are promising in advanced line in KRAS G12C mutated CRC. In this study, We assess the safety and efficacy of 5FU combination with Panitumumab and Sotorasib as first-line treatment in frail/elderly patients with unresectable KRAS G12C mutated CRC
Conditions
- Colorectal Carcinoma
- KRAS G12C Mutation
- Unresectable Colorectal Cancer
Interventions
Administration of experimental treatment association (sotorasib, panitumumab 5FU)Drug
Panitumumab is administered at a dose of 6 mg/kg via intravenous infusion over one hour during the first cycle, and over 30 minutes from the second cycle onward. The LV5FU2 regimen includes folinic acid (400 mg/m², or 200 mg/m² if levo-leucovorin is used) as a two-hour IV infusion, followed by a 5-FU bolus (400 mg/m² over 10 minutes), and a continuous 5-FU infusion (2400 mg/m² over 46 hours). Sotorasib is given orally at a dose of 960 mg once daily on a continuous basis.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Percentage of patient alive or without progression 8 months after inclusion.Time frame: at 8 months after the inclusion.
Locations
80 sites in 4 countries. Site status is shown where the registry gives one.
ICO site Paul Papin
Angers, France
Centre Hospitalier Annecy Genevois
Annecy, France
Hôpital Privé
Antony, France
Centre Hospitalier
Aurillac, France
Centre Hospitalier
Bayeux, France
Ch Cote Basque
Bayonne, France
Ch Simone Veille
Beauvais, France
Chu Jean Minjoz
Besançon, France
Centre Hospitalier Béthune Beuvry
Béthune, France
Polyclinique Courlancy
Bezannes, France
Bordeaux Nord Aquitaine
Bordeaux, France
TIVOLI
Bordeaux, France
Chu Morvan
Brest, France
CHU Côte de Nacre
Caen, France
Centre Hospitalier
Cholet, France
Hôpitaux civils
Colmar, France
Polyclinique Saint-Côme
Compiègne, France
Chu Francois Mitterand
Dijon, France
Gf Leclerc
Dijon, France
Institut de cancérologie de Bourgogne GRReCC
Dijon, France
Groupe Hospitalier Mutualiste
Grenoble, France
Chd Vendee
La Roche-sur-Yon, France
Hôpital Franco Britannique
Levallois-Perret, France
Hôpital Privé Le Bois
Lille, France
CHU Dupuytren
Limoges, France
Groupe Hospitalier Bretagne Sud
Lorient, France
Hôpital Jean Mermoz
Lyon, France
Chu La Timone
Marseille, France
Hôpital Européen
Marseille, France
CHRU
Nancy, France
Gh Nord Essone
Orsay, France
Chu Cochin
Paris, France
HEGP
Paris, France
Montsouris
Paris, France
Saint-Louis
Paris, France
Centre Hospitalier
Pau, France
CHU Haut Leveque
Pessac, France
Centre Cario
Plérin, France
Chu La Miletrie
Poitiers, France
CH Quimper Concarneau
Quimper, France
Showing 40 of 80 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.